Janssen, MeiraGTx sign $440m deal to develop gene therapy programs for IRDs

This article was originally published here

MeiraGTx has five programs in clinical development and a pipeline of preclinical and research programs. As part of a worldwide collaboration and license agreement, the partnership will develop,

The post Janssen, MeiraGTx sign $440m deal to develop gene therapy programs for IRDs appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply